AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society
October 03, 2017 08:00 ET
|
AveXis
– All patients were alive and event-free at 20 months of age as of the August 7, 2017 data cut-off – – Patients in Cohort 2 continue to demonstrate improvements in motor milestones – SAINT MALO,...
AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
September 29, 2017 07:00 ET
|
AveXis
– FDA notified AveXis it may initiate pivotal trial based on a review of data provided by the company following CMC Type B meeting – – Product used in the pivotal...
AveXis Reports Second Quarter 2017 Financial and Operating Results
August 10, 2017 16:01 ET
|
AveXis
– AveXis on track to submit potency assay data to FDA in August – – Conference call and webcast August 10 at 4:30 p.m. EDT – CHICAGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc....
AveXis to Report Second Quarter 2017 Financial and Operating Results
August 03, 2017 08:00 ET
|
AveXis
CHICAGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 26, 2017 16:00 ET
|
AveXis
CHICAGO, June 26, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at...
AveXis Announces Pricing of Public Offering of Common Stock
June 20, 2017 21:14 ET
|
AveXis
CHICAGO, June 20, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,575,000 shares of its common stock. The net proceeds to...
AveXis Announces Proposed Public Offering of Common Stock
June 19, 2017 16:00 ET
|
AveXis
CHICAGO, June 19, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $200 million of shares of its common...
AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
June 14, 2017 16:00 ET
|
AveXis
– Agency is supportive of proposed analytical methods and comparability protocol – – AveXis anticipates initiating U.S. SMA Type 1 and Type 2 trials in Q3 2017 with product from new process – – ...
AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
June 07, 2017 16:00 ET
|
AveXis
CHICAGO and ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and REGENXBIO Inc. (NASDAQ:RGNX) today announced an exclusive worldwide license agreement for AveXis to...
AveXis Reports First Quarter 2017 Financial and Operating Results
May 11, 2017 16:00 ET
|
AveXis
CHICAGO, May 11, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...